Four in five centres have a wait of more than three months, AA figures show
Authorities are rushing to contain latest outbreak fuelled by a more dangerous type of the virus
Jab makers fall behind Moderna in post-pandemic market with disappointing results
Leading producer says it needs orders to ramp up supply with outbreaks surging in central and east Africa
Lobbyists seek ‘meaningful’ consultation to avoid ‘unintended consequences’ of reform
She will be taking on occasional admin work for me
Wild birds are more likely to be carriers of antibiotic-resistant bacteria if they live close to humans, says study
A surge in infections will boost companies’ shares but this sector’s volatility makes them a poor long-term bet
Industry body says inflation-adjusted corporate travel spending will not return to pre-pandemic levels until 2027
A summer Covid outbreak has left staff wondering if they should skip work, come in, or do something in between
Report finds focus on influenza, preparations for no-deal Brexit and ‘groupthink’ strategy hampered response to virus
EU court rules that European Commission unlawfully withheld information about procurement
New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules
Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
Vaccine maker to seek approval for jab as it tries to diversify product pipeline
Total court-issued penalties for breaches higher than any other crime bar motoring offences and TV licence evasion
Simon Case tells inquiry it was ‘very frustrating’ to work for Boris Johnson during Covid crisis
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
Calls for amnesty intensify as total guilty verdicts over pandemic regulations in England top 27,000
So-called FLiRT strains set to test effectiveness of vaccines against latest mutations
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
GSK joins UK government in committing £130mn to tackle growth of antimicrobial resistance
Businesses across hospitality sector have brought dozens of cases in bid to recover some losses
Drugmaker follows Eli Lilly in cutting out middlemen and selling directly to patients
